[HTML][HTML] Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review
M IJzerman-Korevaar, TJ Snijders, A de Graeff… - Journal of neuro …, 2018 - Springer
M IJzerman-Korevaar, TJ Snijders, A de Graeff, SCCM Teunissen, FYF de Vos
Journal of neuro-oncology, 2018•SpringerBackground Glioma patients suffer from a wide range of symptoms which influence quality of
life negatively. The aim of this review is to give an overview of symptoms most prevalent in
glioma patients throughout the total disease trajectory, to be used as a basis for the
development of a specific glioma Patient Reported Outcome Measure (PROM) for early
assessment and monitoring of symptoms in glioma patients. Methods A systematic review
focused on symptom prevalence in glioma patients in different phases of disease and …
life negatively. The aim of this review is to give an overview of symptoms most prevalent in
glioma patients throughout the total disease trajectory, to be used as a basis for the
development of a specific glioma Patient Reported Outcome Measure (PROM) for early
assessment and monitoring of symptoms in glioma patients. Methods A systematic review
focused on symptom prevalence in glioma patients in different phases of disease and …
Background
Glioma patients suffer from a wide range of symptoms which influence quality of life negatively. The aim of this review is to give an overview of symptoms most prevalent in glioma patients throughout the total disease trajectory, to be used as a basis for the development of a specific glioma Patient Reported Outcome Measure (PROM) for early assessment and monitoring of symptoms in glioma patients.
Methods
A systematic review focused on symptom prevalence in glioma patients in different phases of disease and treatment was performed in MEDLINE, CINAHL and EMBASE according to PRISMA recommendations. We calculated weighted means for prevalence rates per symptom.
Results
The search identified 2.074 unique papers, of which 32 were included in this review. In total 25 symptoms were identified. The ten most prevalent symptoms were: seizures (37%), cognitive deficits (36%), drowsiness (35%), dysphagia (30%), headache (27%), confusion (27%), aphasia (24%), motor deficits (21%), fatigue (20%) and dyspnea (20%).
Conclusions
Eight out of ten of the most prevalent symptoms in glioma patients are related to the central nervous system and therefore specific for glioma. Our findings emphasize the importance of tailored symptom care for glioma patients and may aid in the development of specific PROMs for glioma patients in different phases of the disease.
Springer